Ophtha?
- Thread starter anonymous
- Start date
-
- Tags
- None
Anyone? There are openings posted but I heard that they are selling or eliminating the division? I just got let go from my company due to buyout so any info is appreciated
We don’t have any idea what’s happening. But if you have other options take those first. If you need a job immediately go for a Xiidra opening. It’s a crap shoot at this point.
Spot on advice ^^^^
Novartis used to be a mammoth in eyecare, now it doesn’t bother to mention the division on earnings calls or any stage. What a shame. Failure to execute xiidra and Beovu was a disaster. Also been a revolving of franchise heads. This sales team has been through the wringer and market development and TLL teams were recently displaced. It’s a crapshoot as mentioned
Novartis used to be a mammoth in eyecare, now it doesn’t bother to mention the division on earnings calls or any stage. What a shame. Failure to execute xiidra and Beovu was a disaster. Also been a revolving of franchise heads. This sales team has been through the wringer and market development and TLL teams were recently displaced. It’s a crapshoot as mentioned
Xiidra is not going anywhere for the next couple years. It brought in 1.2 billion for Novartis last year. No other eye care company can afford it. Novartis just renewed it's marketing contract for 2023 and will be airing commercials again.
Wow Xiidra brings in that much revenue! Had no idea. I did however see a commercial a few weeks ago
I believe that is all products from novartis ophthalmics including Lucentis. You are correct that no one wants to buy Xiidra. It is too expensive for what Novartis is asking. In a market that will have 3 new branded medications all with new technologies and specific areas of dry rye treatment, a bigger push to out of pocket procedures, and not to mention 13 generic versions of cyclosporine generic Novartis knows the eye care ship is sinking. Its not going to be too long until the sales force goes the way of respiratory and reduces head count by 50%.
Xiidra was around 550 million last year. It was 440 when Novartis bought it for 4 billion in 2018. 110 million over a 6 year period is definitely not what Novartis had planned. Like the poster above said the market is about to get new treatments and a bigger generic presence. Where do you see the drug going under those conditions? You think they cut professional relations, VSS team, and then say ok lets stop there? Wake up if you believe that. Theres a reason all leadership parrot the same taglines when asked about future of eye care. Yeah the division may be here in a year, but do ypu really think it will be with same headcount on a 7 year old drug not doing nearly as well as predicted?
Not to mention that every article that speaks of novartis not selling starts with “currently not selling” and makes no mention of Xiidra, but speaks of Lucentis and beovu. Plus the fact Xiidra was purchased to “limp us along” until the new drop came out, which now…
Hey, we do have a lot of assets being researched…….think in phase . So we should see a new drug in about 6 years.
But six years is a loooong time to continue just promoting Xiidra don’t you think?
Yes the numbers are off. They are even worse than what the person said lol
Bruh. If you think novartis is gonna keep this current team selling one drug for six years and no chance of acquiring no other Optha product, I’ve got a bridge I wanna sell ya.
Listen brosef, if you cant tell the difference between sarcasm and a real post I have a lot more I can sell you than a bridge. Not sure what world waiting 6 years for a new drug would be a good thing.
that is 100% inaccurate. Xiidra a billion dollars??? Hahaha
hey, give the guy a break. We all know hq gets on here and sells sunshine…
